The amniotic fluid as a source of cells for fetal tissue engineering

Kaviani, Amir; Perry, Tjörvi E.; Dzakovic, Alexander; Jennings, Russell W.; Ziegler, Moritz M.; Fauza, Dario O.

doi:10.1053/jpsu.2001.27945

Cited by 228 publications

(142 citation statements)

References 21 publications

Supporting

Mentioning

128

Contrasting

Unclassified

Order By: Relevance

“…The mesenchymal cell population was isolated from the amniotic samples based on methods as previously described by our group [1,5]. Briefly, the sample was centrifuged at 400 g for 15 minutes.…”

Section: Isolation and Primary Expansionmentioning

confidence: 99%

“…Among the different progenitor cell lineages naturally occurring in the amniotic fluid, the mesenchymal population has proven valuable in pre-clinical, large animal models of cell-based surgical therapy, through amniotic fluid-based fetal tissue engineering [1][2][3][4]. The concept involves the diagnosis of a structural birth defect by prenatal imaging, followed by isolation and expansion of amniotic mesenchymal stem cells (AMSCs) from a routine amniocentesis sample, which are then used to engineer a variety of tissue constructs in parallel to the remainder of gestation, so that a newborn, or fetus, could benefit from the availability of an autologous, custom-made graft for surgical repair of a given congenital anomaly [1][2][3][4][5][6][7].…”

mentioning

confidence: 99%

“…The concept involves the diagnosis of a structural birth defect by prenatal imaging, followed by isolation and expansion of amniotic mesenchymal stem cells (AMSCs) from a routine amniocentesis sample, which are then used to engineer a variety of tissue constructs in parallel to the remainder of gestation, so that a newborn, or fetus, could benefit from the availability of an autologous, custom-made graft for surgical repair of a given congenital anomaly [1][2][3][4][5][6][7].…”

mentioning

confidence: 99%

See 2 more Smart Citations

Preclinical regulatory validation of a 3-stage amniotic mesenchymal stem cell manufacturing protocol

Steigman

Armant

Bayer-Zwirello

et al. 2008

Journal of Pediatric Surgery

Self Cite

View full text Add to dashboard Cite

Purpose-Due to the 4-6-month interval between a diagnostic amniocentesis and birth, clinical application of amniotic mesenchymal stem cell (AMSC)-based therapies demands a 3-stage cell manufacturing process, including isolation/primary expansion, cryopreservation, and thawing/ secondary expansion. We sought to determine the feasibility and cell yield of such a staged cell manufacturing process, within regulatory guidelines. Methods-HumanAMSCs isolated from diagnostic amniocentesis samples (n=11) were processed under FDA-accredited Good Manufacturing Practice. Expanded cells were characterized by flow cytometry and cryopreserved for 3-5 months. Cell release criteria included: >90% CD29+, CD73+, and CD44+; <5% CD34+ and CD45+; negative mycoplasma QPCR and endotoxin assay; and ≥70% viability.Results-Isolation and ample expansion of AMSCs was achieved in 54.5% (6/11) of the samples. Early processing and at least a 2mL sample were necessary for reliable cell manufacturing. Cell yield before cryopreservation was 223.2±65.4×10 6 cells (44.6-fold expansion), plus a 14.7×10 6 -cell backup, after 36.3±7.8 days. Cell viability post-thaw was 88%. Expanded cells maintained a multipotent mesenchymal progenitor profile.Conclusions-Human amniotic mesenchymal stem cells can be manufactured in large numbers from diagnostic amniocentesis, by an accredited staged processing, under definite procurement guidelines. These data further support the viability of clinical trials of amniotic mesenchymal stem cell-based therapies.

show abstract

Section: Isolation and Primary Expansionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Preclinical regulatory validation of a 3-stage amniotic mesenchymal stem cell manufacturing protocol

Steigman

Armant

Bayer-Zwirello

et al. 2008

Journal of Pediatric Surgery

Self Cite

View full text Add to dashboard Cite

show abstract

“…It is already possible to gain access to fetal cells and to grow them selectively. This offers therapeutic potential (208), and such tissue engineering has already occurred (209).…”

Section: What Does the Future Hold?mentioning

confidence: 99%

The Evolution of Neonatology

Philip

2005

Pediatr Res

544

View full text Add to dashboard Cite

In 1960, the terms "neonatology" and "neonatologist" were introduced. Thereafter, an increasing number of pediatricians devoted themselves to full-time neonatology. In 1975, the first examination of the Sub-Board of Neonatal-Perinatal Medicine of the American Board of Pediatrics and the first meeting of the Perinatal Section of the American Academy of Pediatrics were held. One of the most important factors that improved the care of the neonate was the miniaturization of blood samples needed to determine blood gases, serum electrolytes, glucose, calcium, bilirubin, and other biochemical measurements. Another factor was the ability to provide nutrition intravenously, and the third was the maintenance of normal body temperature. The management of respiratory distress syndrome improved with i.v. glucose and correction of metabolic acidosis, followed by assisted ventilation, continuous positive airway pressure, antenatal corticosteroid administration, and the introduction of exogenous surfactant. Pharmacologic manipulation of the ductus arteriosus, support of blood pressure, echocardiography, and changes in the management of persistent pulmonary hypertension, including the use of nitric oxide and extracorporeal membrane oxygenation, all have influenced the cardiopulmonary management of the neonate. Regionalization of neonatal care; changes in parent-infant interaction; and technological changes such as phototherapy, oxygen saturation monitors, and brain imaging techniques are among the important advances reviewed in this report. Most remarkable, a 1-kg infant who was born in 1960 had a mortality risk of 95% but had a 95% probability of survival by 2000. However, errors in neonatology are acknowledged, and potential directions for the future are explored. Abbreviations AAP, American Academy of Pediatrics BPD, bronchopulmonary dysplasia CPAP, continuous positive airway pressure ECMO, extracorporeal membrane oxygenation ELBW, extremely low birth weight HMD, hyaline membrane disease iNO, inhaled nitric oxide IUGR, intrauterine growth restriction IVH, intraventricular hemorrhage L/S, ratio of lecithin, phosphatidyl choline, to sphingomyelin NICU, neonatal intensive care unit PDA, patent ductus arteriosus PEEP, positive end expiratory pressure PPHN, persistent pulmonary hypertension of the newborn PVH, periventricular hemorrhage RDS, respiratory distress syndrome ROP, retinopathy of prematurity SIDS, sudden infant death syndrome VLBW, very low birth weight VON, Vermont-Oxford Network "There is need for specialization in neonatal medicine. This applies to doctors and nurses as well as teaching and construction of hospitals. The specialist in neonatal diseases and the nurse intensively trained and expert in the management of delicate newborns will be commonplace ere long." J.W. Ballantyne, 1923 (1) "In previous times the problems of the newborn child have been the province of the obstetrician, a field in which he has taken comparatively little interest and to which he has contributed little. As pediatricians we have but s...

show abstract

“…22 Por outro lado, em trabalho pioneiro, foi identificado um tipo celular com características de rápida proliferação, com positividade para vimentina, actina de músculo liso (SMA), citoqueratina 8 e 18 e proteína de superfície de fibroblastos (SFP), e negatividade para desmina e CD31; e confirma-se a descendência de linhagem mesenquimal (fibroblástica/miofibroblástica). 23,24 Foram demonstrados, ainda, precursores neurais e células neuronais diferenciadas, mesmo em gestações em que não ocorre defeito aberto de tubo neural. 25 Tais células expressam, ao lado de marcadores mesenquimais, outros relacionados a células neuronais, como NES (nestina), TUBB3 (tubulin β -3), NEFH (neuronal nuclear antigen A60), GALC (galactosilceramidase) e GFAP (glial fibrilary acidic protein).…”

unclassified

Células-tronco do líquido amniótico

Bydlowski¹,

Debes²,

Duarte³

et al. 2009

Rev. Bras. Hematol. Hemoter.

View full text Add to dashboard Cite

Células-tronco do líquido amniótico Amniotic fluid stem cells IntroduçãoO fluido amniótico humano tem sido utilizado no diagnóstico pré-natal já há mais de 70 anos. O primeiro relato sobre amniocentese foi em 1930, no qual os autores tentaram correlacionar o número de células presentes no líquido amniótico e o fenótipo celular com o sexo e a saúde do feto. Atualmente, uma das principais utilizações diagnósticas do líquido amniótico é no isolamento de células fetais para cariotipagem, no exame de anormalidades cromossômicas. Recentemente, foram apresentadas evidências de que o lí-quido amniótico pode ter outras aplicações, além da utilização como ferramenta diagnóstica. Ele pode ser importante fonte de células terapêuticas para vários distúrbios, tanto congênitos quanto no adulto.O líquido amniótico contém uma quantidade muito grande de células em suspensão, população celular que é variá-vel com a fase da gestação e que traduz as mudanças na formação do líquido amniótico e da maturação fetal e de seus anexos.

show abstract

The amniotic fluid as a source of cells for fetal tissue engineering

Cited by 228 publications

References 21 publications

Preclinical regulatory validation of a 3-stage amniotic mesenchymal stem cell manufacturing protocol

Preclinical regulatory validation of a 3-stage amniotic mesenchymal stem cell manufacturing protocol

The Evolution of Neonatology

Células-tronco do líquido amniótico

Contact Info

Product

Resources

About